One pathway, two diseases: the shared complement alternative pathway biology

Geographic atrophy (GA) and C3 glomerulopathy (C3G) are driven by the same molecular fault: dysregulation of the complement alternative pathway (CAP), which triggers pathological C3 fragment deposition in the retina and glomerulus respectively. In GA—the advanced form of dry age-related macular degeneration—local overactivation of the C3b feedback cycle destroys retinal pigment epithelium and photoreceptors. In C3G, a rare disease with an estimated prevalence of 2–3 per 1,000,000 people, uncontrolled CAP activation deposits C3d in glomeruli, causing hematuria, proteinuria, and progressive renal failure.

The molecular targets documented in the patent dataset reflect this shared biology. Complement Factor B (CFB) is the rate-limiting enzyme of the CAP amplification loop: its inhibition prevents assembly of the C3 convertase (C3bBb) and downstream C3 deposition in both ocular and glomerular compartments. Complement C3 itself sits at the central amplification node of all three complement pathways and is targeted both upstream via RNA interference and downstream via engineered proteases. Complement Factor I (CFI) and Factor H (FH) are regulatory proteins that inactivate C3b; their deficiency or antagonism by Factor H-related proteins (FHR1–5) is cited in patent filings as a driver of both AMD and kidney disease. Terminal pathway nodes C5 and C5aR are also represented, as is soluble complement receptor type I (sCR1), a broad-spectrum inhibitor.

Patent filings from Ionis Pharmaceuticals explicitly cite genetic studies showing that hereditary complement regulatory protein deficiencies predispose individuals to both atypical hemolytic uremic syndrome (aHUS) and AMD, providing a molecular rationale for pursuing both GA and C3G within single drug development programs. Academic literature recovered in the dataset—including a 2022 review from St. Louis, Missouri, titled “Complement-ary Therapies for Age-Related Macular Degeneration”—confirms the scientific consensus around complement dysregulation in AMD pathogenesis. According to WIPO, complement biology represents one of the fastest-growing areas of biopharmaceutical patent activity globally, reflecting the breadth of unmet need across complement-mediated diseases.

The patent landscape: who owns what across eight therapeutic modalities

Complement-targeting therapy for GA and C3G is pursued through at least eight distinct modalities in the retrieved patent dataset, with commercial IP activity dominating over academic literature. Ionis Pharmaceuticals holds the broadest position, but gene therapy, engineered proteases, antibody-fusion proteins, and RNA interference are each represented by distinct assignee clusters with non-overlapping IP strategies.

Antisense oligonucleotides: Ionis Pharmaceuticals’ dominant CFB position

Ionis Pharmaceuticals (formerly ISIS Pharmaceuticals) holds the most extensive IP position in this dataset, with at least nine patent families covering CFB-specific ASO inhibitors across jurisdictions including WO, IL, CA, SG, AU, MX, CN, and JP. Lead compounds include ISIS 696844, ISIS 696845, ISIS 698969, and ISIS 698970. The mechanism involves modified oligonucleotides that suppress CFB mRNA expression in both the retina and the glomerulus, reducing C3 convertase assembly and downstream C3 deposition. Patent activity spans 2015–2025, with 2024–2025 filings describing adaptive dose-monitoring methods that compare circulating CFB levels at sequential timepoints to titrate compound 696844—a signal that dose-optimization clinical protocols are being developed.

Gene therapy: the CFI augmentation rationale

Cambridge Enterprise Limited (licensing entity for the University of Cambridge) and The Sydney Children’s Hospitals Network hold convergent patent families in CN, WO, and JP jurisdictions covering recombinant viral vector delivery of codon-optimized CFI transgenes. The therapeutic rationale is that systemic CFI deficiency is a driving lesion in AMD/GA, and vector-mediated CFI expression restores C3b inactivation capacity. A key mechanistic advantage of CFI over Factor H augmentation is documented explicitly in the filings: CFI circulates at approximately 35 μg/mL compared to Factor H at 200–500 μg/mL, making gene supplementation more tractable. Additionally, Factor H-related proteins (FHR1–5) can competitively antagonize Factor H binding—a complication cited as rationale for preferring CFI augmentation. Gyroscope Therapeutics Limited appears as the commercial development partner, holding related patents covering codon-optimized CFI for ophthalmic use and a combination nucleic acid encoding both anti-VEGF (aflibercept) and CFI/FHL1.

Antibody-based and fusion protein strategies

Multiple distinct antibody-based approaches are documented. Kira Pharmaceuticals (US) LLC claims anti-C5/Factor H fusion proteins for C3G and IgA nephropathy, with a 2025 JP filing containing explicit dosing schedules—1200 mg IV initial dose, 720 mg SC or 600 mg IV weekly maintenance—a strong indicator of clinical-stage pharmacokinetic data. Vitarra Company (威特拉公司) has filed CN patents on anti-C3b antibodies with endpoints including hematuria, proteinuria, acute kidney injury, and CKD. Q32 Bio Inc. holds JP and TW filings for fusion protein constructs combining antibody targeting moieties with complement regulator proteins (CR1, DAF/CD55, MCP/CD46, CD59, FH), measured by urine albumin-to-creatinine ratio. Alexion Pharmaceuticals has filed renal-active fusion proteins incorporating Factor H catalytic domains with VHH single-domain camelid antibody domains targeting kidney epithelial cells for C3G, FSGS, and DDD. Genentech claims CRIg-Fc fusion proteins for AMD via alternative pathway inhibition through the macrophage-specific receptor CRIg. As noted by the FDA, complement-directed biologics represent an increasingly active area of regulatory review given the expansion of approved agents in complement-mediated diseases.

C3 suppression via RNAi and engineered proteases

AstraZeneca (Ireland) Limited has filed a CN patent covering siRNA targeting complement component C3 mRNA, with indication coverage including C3G, GA, DDD, IgA nephropathy, and aHUS. This represents a distinct upstream approach from CFB ASOs—directly suppressing the central complement amplifier rather than the convertase component. Catalyst Biosciences and Vertex Pharmaceuticals hold overlapping patent families across SG, IL, CO, MX, PE, CN, and JP on modified urokinase-type plasminogen activator (u-PA) polypeptides and modified MTSP-1 polypeptides engineered to physically cleave and degrade the C3 substrate, covering AMD/GA, diabetic retinopathy, and transplant rejection. ChemoCentRyx holds IL and BR patents for C5aR antagonist treatment of C3G, exploiting the fact that C5a—generated downstream of C3 cleavage—drives pro-inflammatory macrophage and neutrophil recruitment in the glomerulus via C5aR. The University of Iowa Research Foundation filed WO and EP patents disclosing soluble complement receptor type I (sCR1) for aHUS, dense deposit disease, and C3G through decay-accelerating and cofactor activities of CR1.

“Across at least nine patent families spanning 2015–2025 in six jurisdictions, Ionis Pharmaceuticals has built a broad CFB ASO portfolio explicitly covering both geographic atrophy and C3 glomerulopathy—competitors entering with oligonucleotide mechanisms targeting CFB will need to design around this IP estate.”

Clinical translation signals and what the patent record reveals

The patent record for complement-targeting therapies in GA and C3G contains several credible signals of clinical translation, even where no regulatory approvals are documented in the dataset. These signals range from explicit Phase III trial references to dosing schedule disclosures and biomarker-linked efficacy claims.

The most significant clinical reference in the dataset is the Phase III MAHALO trial of lampalizumab, an anti-Factor D humanized antibody developed by Genentech/Roche for GA. The trial enrolled 906 participants and failed to reduce GA enlargement versus sham over 48 weeks. Multiple patent filings—from Gyroscope Therapeutics, Cambridge Enterprise, and Sydney Children’s Hospitals Network—explicitly cite this failure as motivation for the CFI gene therapy approach and for multi-target combination strategies. The lampalizumab failure is significant for the field because it demonstrates that single-node upstream CAP inhibition may be insufficient in heterogeneous GA patient populations, lending credibility to the CFI augmentation rationale and to biomarker-based patient selection strategies. As noted in research published by the New England Journal of Medicine, the challenge of demonstrating efficacy in GA trials reflects both the heterogeneity of disease progression and the difficulty of identifying patients most likely to benefit from complement inhibition.

Kira Pharmaceuticals’ 2025 JP filing for its anti-C5/FH fusion protein contains explicit dosing schedules—1200 mg IV initial dose followed by 720 mg SC or 600 mg IV weekly maintenance—which is a strong indicator of clinical-stage pharmacokinetic and pharmacodynamic data underpinning the filing. ChemoCentRyx’s IL and BR patent filings explicitly reference treatment of specific human patient populations susceptible to C3G with a C5aR antagonist (avacopan-class), suggesting these filings were prepared in the context of ongoing or planned clinical investigation.

The Regeneron Pharmaceuticals JP and SG patents describe IND-enabling humanized C3 animal model work with C5b-9 membrane attack complex (MAC) formation as a surrogate endpoint, consistent with an IND-enabling preclinical package. The humanized C3 model is positioned as a preclinical screening tool for C3-targeting therapeutics in complement-associated nephropathy, measuring both glomerular C3 deposition and MAC formation as efficacy readouts.

No retrieved result in this dataset directly documents an approved drug for GA or C3G based on complement targeting, and no regulatory approval decisions are documented. The dataset represents a snapshot of patent and literature signals only and should not be interpreted as a comprehensive clinical pipeline view. For authoritative regulatory status information, the European Medicines Agency and the FDA maintain public databases of approved and investigational complement-directed therapies.

Combination strategies and the emerging precision medicine frontier

The most recent patent filings in this dataset—predominantly from 2023 to 2025—signal a clear shift from single-target complement inhibition toward combination modalities, organ-targeted delivery, and biomarker-guided patient selection. These strategies address the efficacy limitations of monotherapy in heterogeneous patient populations and represent the emerging frontier of complement-directed drug development.

Complement plus anti-VEGF dual inhibition for AMD/GA

Three separate assignees have filed patents on complement plus VEGF dual inhibition for AMD/GA. Gyroscope Therapeutics (MX, 2023) explicitly claims a nucleic acid combination encoding both anti-VEGF (aflibercept) and CFI/FHL1 as a combined preparation for AMD. Innovent Biologics (Suzhou) Company Limited (JP, 2023) covers bispecific fusion proteins simultaneously inhibiting complement and VEGF pathways, positioning the bifunctional approach as superior to sequential intravitreal injections. Sanyo Biotechnology (三钰生物科技股份有限公司) (CN, 2021) covers dual-target complement/VEGF fusion proteins using all-human sequences. The convergence of three assignees on this combination format within a short filing window suggests that complement plus anti-VEGF is becoming a consensus strategy for overcoming monotherapy limitations in GA.

Anti-C5 antibody plus C5 RNAi co-formulation

Regeneron’s CN filing (2025) describes a co-formulation of an anti-C5 antibody with GalNAc-conjugated C5 siRNA to achieve deeper and more durable C5 suppression than monotherapy can achieve, targeting PNH and related C5-mediated diseases. This mechanistically layered combination—an antibody blocking C5 protein while siRNA suppresses C5 mRNA—represents a dual-mechanism approach to terminal complement blockade that is distinct from all other modalities in the dataset.

Kidney-targeted organ delivery via VHH domains

Alexion Pharmaceuticals’ CN filing on renal-active fusion proteins uses VHH (single-domain camelid antibody) domains to deliver Factor H catalytic domains selectively to kidney epithelial cells, moving beyond systemic complement blockade toward precision organ targeting. This approach is explicitly claimed for C3G, FSGS, and DDD, and signals a direction in which complement inhibition is delivered with the specificity of a targeted therapy rather than as a systemic immunosuppressant. The University of Leicester’s CN filing on MASP-2 inhibitory antibodies for IgA nephropathy also mentions C3G, signaling that lectin pathway-targeting approaches are being considered adjacent to CAP-directed strategies for complement kidney diseases.

Patient stratification as both clinical strategy and IP asset

Oak Bay Biosciences’ 2025 WO filing on complement pathway activity biomarkers for pre-selecting GA patients represents the only retrieved assignee explicitly claiming companion diagnostic stratification linked to complement therapy efficacy. The quantified efficacy differential—at least approximately 40% greater GA slowing in patients with hyperactive complement pathway activity—suggests that biomarker-enriched trial designs could substantially improve the probability of demonstrating efficacy in GA trials where unselected populations have historically shown modest treatment effects. The development of companion diagnostics linked to complement-targeting therapies represents both a regulatory strategy and a potential IP asset that remains largely unclaimed in this dataset.

Strategic implications for drug developers and IP teams

The patent landscape for complement-targeting therapies in GA and C3G presents both well-defended positions and underexploited opportunities. Five strategic observations emerge from the dataset for drug developers, IP counsel, and R&D leaders evaluating this space.

First, the CFB ASO space is heavily defended by Ionis. Across at least nine patent families spanning 2015–2025 in six jurisdictions, Ionis Pharmaceuticals has built a broad CFB ASO portfolio explicitly covering both GA and C3G. Competitors entering these indication spaces with oligonucleotide mechanisms targeting CFB will need to design around this IP estate or pursue licensing arrangements. The sustained prosecution activity from 2015 through 2025 indicates active portfolio management rather than abandoned filings.

Second, pursuing both GA and C3G within a single program has documented precedent and IP value. Multiple assignees—Ionis, AstraZeneca, Catalyst Biosciences, Alexion, Q32 Bio—explicitly claim both ocular and kidney indications within single patent families, reflecting the shared CAP biology. Drug developers targeting one indication should assess the regulatory and IP value of pursuing both diseases within a single program, as the shared mechanism supports a single IND-enabling biology package.

Third, CFI gene therapy represents a differentiated and potentially protected niche. Only Cambridge Enterprise/Gyroscope Therapeutics hold substantial IP in CFI gene therapy for GA, with a mechanistic rationale directly addressing the failure of upstream CAP inhibitors (lampalizumab). The dual function of CFI—cleavage of C3b to iC3b and acceleration of iC3b degradation to C3dg, reducing complement-induced inflammation via CR3 signaling—provides a differentiated mechanism. This niche may be protected if clinical translation succeeds.

Fourth, combination modality IP represents the emerging competitive frontier. Multiple assignees are filing patents on complement plus VEGF dual inhibition for AMD, complement antibody plus siRNA co-formulations for C5 diseases, and targeted organ-delivery fusion proteins. First-mover IP in defined combination formats could be valuable as monotherapy complement inhibitors face efficacy limitations in heterogeneous patient populations. The three-year window of 2023–2025 represents the highest-density period of combination filing activity in this dataset.

Fifth, biomarker-driven patient stratification is an underexploited IP and clinical opportunity. Only one retrieved assignee—Oak Bay Biosciences—explicitly claims complement pathway activity profiling for patient selection in GA trials. Given the documented ~40% efficacy differential in hyperactive complement patients, the development of companion diagnostics linked to complement-targeting therapies represents both a regulatory strategy and a potential IP asset that remains largely unclaimed. As the WHO has noted in its guidance on rare disease drug development, companion diagnostic co-development is increasingly expected by regulators for precision medicine approaches in ultra-rare conditions such as C3G.

“Only one retrieved assignee explicitly claims complement pathway activity profiling for patient selection in GA trials—yet subjects with hyperactive complement pathway activity experience at least approximately 40% more slowing of geographic atrophy. Companion diagnostics linked to complement-targeting therapies remain a largely unclaimed IP and clinical opportunity.”

The emergence of Chinese biotech IP activity in complement-directed biologics—represented by Vitarra Company’s CN anti-C3b antibody filing and Sanyo Biotechnology’s dual-target fusion protein—signals that the competitive landscape is broadening geographically. Drug developers with existing complement IP should assess freedom-to-operate in CN jurisdiction specifically, given the increasing density of Chinese complement biology filings documented in this dataset. For a comprehensive view of global complement therapy patent activity, PatSnap’s life sciences intelligence platform provides real-time monitoring across all major jurisdictions.